NTRA — Natera Inc. stock price and chart

NTRA

Natera Inc.Stock · Health CareNasdaq Composite 0.07% · Russell 1000 0.05% · Russell 3000 0.05% · US Stock Market 0.05% · MSCI World 0.03% · MSCI ACWI 0.03%

$369.39+0.84%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

50.0100.0150.0200.0250.0300.0350.0050.0M$369.39

2026-09-18

Price$369.39

MA20$262.50

MA50$222.81

Vol9.5M

What would $1,000 invested in NTRA be worth today? →

NTRA returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $369.39
Change YTD: +61.24%
Next earnings: Nov 5, 2026
Market cap: 53.2B2016-09 582M2026-09 53.2B+9049.2% over the window
Enterprise value: 52.4B
Shares outstanding: 144.1M2016-06 51.8M2026-06 144.1M+178.4% over the window
52W low: $157.43
52W high: $369.69
From 52W high: -0.08%
From 52W low: +134.65%
52W range: 100%
Beta: 1.50

Volume

Rel volume: 2.59×
30D volume: 1.4M
30D $ vol: 476.1M

Fundamentals

Sales (ttm): 2.7B2016-06 211.7M2026-06 2.7B+1178.6% over the window
Sales/share: $18.782016-06 $4.092026-06 $18.78+359.3% over the window
EPS (ttm): -$1.372016-06 -$1.482026-06 -$1.37-7.4% over the window
FCF (ttm): 84.2M2016-06 -51.3M2026-06 84.2M-264.2% over the window
FCF/share: $0.582016-06 -$0.992026-06 $0.58-159.0% over the window
Book value/share: $12.642016-06 $3.162026-06 $12.64+299.4% over the window
Net margin: -7.11%2016-06 -34.2%2026-06 -7.1%-79.2% over the window
ROE: -10.56%2016-06 -44.2%2026-06 -10.6%-76.1% over the window
ROA: -7.24%2016-06 -27.7%2026-06 -7.2%-73.9% over the window
Current ratio: 3.002016-06 2.482026-06 3.00+20.7% over the window

Growth (CAGR, ttm) · 10Y

Sales: +37.85%2025-06-30 → 2026-06-302B → 2.7B (+37.8% total)+42.72%2023-06-30 → 2026-06-30931M → 2.7B (+190.8% total)+39.92%2021-06-30 → 2026-06-30504.9M → 2.7B (+436.2% total)+29.03%2016-06-30 → 2026-06-30211.7M → 2.7B (+1178.6% total)
FCF: -19.48%2025-06-30 → 2026-06-30104.6M → 84.2M (-19.5% total)n/an/an/a
Shares: +5.03%2025-06-30 → 2026-06-30137.2M → 144.1M (+5.0% total)+7.94%2023-06-30 → 2026-06-30114.6M → 144.1M (+25.8% total)+8.98%2021-06-30 → 2026-06-3093.8M → 144.1M (+53.7% total)+10.78%2016-06-30 → 2026-06-3051.8M → 144.1M (+178.4% total)

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +31.25%2025-06-30 → 2026-06-30$14.31 → $18.78 (+31.2% total)+32.21%2023-06-30 → 2026-06-30$8.12 → $18.78 (+131.2% total)+28.39%2021-06-30 → 2026-06-30$5.38 → $18.78 (+248.9% total)+16.47%2016-06-30 → 2026-06-30$4.09 → $18.78 (+359.3% total)
FCF/share: -23.34%2025-06-30 → 2026-06-30$0.76 → $0.58 (-23.3% total)n/an/an/a
Book value/share: +39.21%2025-06-30 → 2026-06-30$9.08 → $12.64 (+39.2% total)+34.42%2023-06-30 → 2026-06-30$5.20 → $12.64 (+142.9% total)+31.70%2021-06-30 → 2026-06-30$3.19 → $12.64 (+296.2% total)+14.86%2016-06-30 → 2026-06-30$3.16 → $12.64 (+299.4% total)
Price: +105.48%2025-09-18 → 2026-09-18$179.86 → $369.39 (+105.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+93.38%2023-09-18 → 2026-09-18$51.06 → $369.39 (+623.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+23.92%2021-09-17 → 2026-09-18$126.36 → $369.39 (+192.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+43.13%2016-09-16 → 2026-09-18$10.22 → $369.39 (+3514.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +105.48%2025-09-18 → 2026-09-18$179.86 → $369.39 (+105.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+93.38%2023-09-18 → 2026-09-18$51.06 → $369.39 (+623.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+23.92%2021-09-17 → 2026-09-18$126.36 → $369.39 (+192.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+43.13%2016-09-16 → 2026-09-18$10.22 → $369.39 (+3514.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -269.0×2016-09 -7.202026-09 -276.82+3744.2% over the window
Fwd P/E: -3589.4×
P/S (ttm)Market cap ÷ TTM revenue.: 19.7×2016-09 2.642026-09 19.67+645.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 29.2×2016-09 4.152026-09 29.23+604.8% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 632.4×2016-09 -8.942026-09 632.39-7171.0% over the window
EV/Sales (ttm): 19.4×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 0.16%2016-06 -8.8%2026-06 0.2%-102.4% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 144.1M ÷ 137.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -5.03%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-5.03%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($23.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -5.03%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($53.2B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-06 0.1%2026-06 0.0%-100.0% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($53.2B). Same caveat as the cash buyback yield.: 0.00%2016-06 0.1%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/S: 93rd
P/B: 91st

Bar = where today’s multiple sits in NTRA’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

+0.84%

+12.30%

+18.51%

+59.63%

YTD

+61.24%

+105.38%

+192.33%

Financial statements

Open full NTRA financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-9.18%	-0.39%
NVO	Novo Nordisk A/S	-5.40%	+0.12%
SNY	Sanofi ADS	-5.54%	-1.53%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-1.82%	-1.65%
ARGX	argenx SE American Depositary Shares	-0.27%	-0.55%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	+4.76%	-0.73%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+6.56%	-0.54%
RVMD	Revolution Medicines Inc.	-11.60%	-3.04%

Natera Inc. (NTRA) trades at $369.39 with a live price and an interactive chart covering 11+ years of daily price history, plus key valuation metrics. ChartRow also publishes NTRA’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full NTRA financial statements →

NTRA — Natera Inc. price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · as of 2026-09-18

Financial statements

Related Health Care